REYKJAVIK, Iceland, June 19 /PRNewswire-FirstCall/ -. deCODE genetics today announced that it will webcast live the presentations at the company’s annual R&D event being held in Reykjavik on Monday, June 25, 2007. deCODE management will present overviews of progress in the company’s drug development, drug discovery, diagnostics and gene discovery programs, as well as updates on finance, intellectual property and corporate alliances. The program will begin at 9am GMT/5am Eastern Time, and is expected to last approximately four hours.
The webcast can be accessed through the Investors page on deCODE’s website, http://www.decode.com. Those interested in listening should log on a few minutes in advance in order to download any software or complete any sign- in that may be required. The presentations will be archived on deCODE’s website and the archived version will be made available shortly after the conclusion of the event.
About deCODE
deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of drugs and diagnostics for common diseases. deCODE is a global leader in gene discovery -- our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. deCODE is also leveraging its expertise in human genetics and integrated drug discovery and development capabilities to offer innovative products and services in DNA-based diagnostics, bioinformatics, genotyping, structural biology, drug discovery and clinical development. deCODE is delivering on the promise of the new genetics(SM). Visit us on the web at http://www.decode.com.
Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties include, among others, those relating to technology and product development, integration of acquired businesses, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in deCODE’s filings with the Securities and Exchange Commission. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.
Contact: deCODE genetics Stefan Arnason +354 570 1995 ir@decode.is
deCODE genetics
CONTACT: Stefan Arnason of deCODE genetics, +354-570-1995, ir@decode.is
Web site: http://www.decode.com/
